Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Letter
Nature Medicine - 12, 122 - 127 (2005)
Published online: 11 December 2005; | doi:10.1038/nm1337

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

George V Thomas1, Chris Tran2, Ingo K Mellinghoff3, 4, 5, Derek S Welsbie3, Emily Chan1, Barbara Fueger4, Johannes Czernin4 & Charles L Sawyers2, 3, 4, 6

1  Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

2  Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

3  Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

4  Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

5  Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

6  Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

Correspondence should be addressed to Charles L Sawyers csawyers@mednet.ucla.edu

Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity in cancer trials, leading to confusion about the appropriate clinical setting for their use. Here we show that loss of the Von Hippel-Lindau tumor suppressor gene (VHL) sensitizes kidney cancer cells to the mTOR inhibitor CCI-779 in vitro and in mouse models. Growth arrest caused by CCI-779 correlates with a block in translation of mRNA encoding hypoxia-inducible factor (HIF1A), and is rescued by expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region. VHL-deficient tumors show increased uptake of the positron emission tomography (PET) tracer fluorodeoxyglucose (FDG) in an mTOR-dependent manner. Our findings provide preclinical rationale for prospective, biomarker-driven clinical studies of mTOR inhibitors in kidney cancer and suggest that FDG-PET scans may have use as a pharmacodynamic marker in this setting.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

TORward AKTually useful mouse models

Nature Medicine News and Views (01 Jun 2004)

Oxygen deprivation provokes melanoma

Nature Medicine News and Views (01 Feb 2006)

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
rights and permissionsRights and permissions
Order commercial reprintsOrder commercial reprints
CrossRef lists 60 articles citing this articleCrossRef lists 60 articles citing this article
Save this linkSave this link
Figures & Tables
Supplementary info
Export citation

Open Innovation Challenges

naturejobs

natureproducts

Search buyers guide:

 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2006 Nature Publishing Group | Privacy policy